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Constitutive overexpression of the MDR1 (multidrug resistance) gene, which encodes a multidrug efflux pump of the
major facilitator superfamily, is a frequent cause of resistance to fluconazole and other toxic compounds in clinical
Candida albicans strains, but the mechanism of MDR1 upregulation has not been resolved. By genome-wide gene
expression analysis we have identified a zinc cluster transcription factor, designated as MRR1 (multidrug resistance
regulator), that was coordinately upregulated with MDR1 in drug-resistant, clinical C. albicans isolates. Inactivation of
MRR1 in two such drug-resistant isolates abolished both MDR1 expression and multidrug resistance. Sequence analysis
of the MRR1 alleles of two matched drug-sensitive and drug-resistant C. albicans isolate pairs showed that the resistant
isolates had become homozygous for MRR1 alleles that contained single nucleotide substitutions, resulting in a P683S
exchange in one isolate and a G997V substitution in the other isolate. Introduction of these mutated alleles into a
drug-susceptible C. albicans strain resulted in constitutive MDR1 overexpression and multidrug resistance. By
comparing the transcriptional profiles of drug-resistant C. albicans isolates and mrr1D mutants derived from them and
of C. albicans strains carrying wild-type and mutated MRR1 alleles, we defined the target genes that are controlled by
Mrr1p. Many of the Mrr1p target genes encode oxidoreductases, whose upregulation in fluconazole-resistant isolates
may help to prevent cell damage resulting from the generation of toxic molecules in the presence of fluconazole and
thereby contribute to drug resistance. The identification of MRR1 as the central regulator of the MDR1 efflux pump and
the elucidation of the mutations that have occurred in fluconazole-resistant, clinical C. albicans isolates and result in
constitutive activity of this trancription factor provide detailed insights into the molecular basis of multidrug resistance
in this important human fungal pathogen.
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Introduction
The yeast Candida albicans is usually a harmless commensal
in many healthy people where it resides on mucosal surfaces
of the gastrointestinal and urogenital tract, but it can also
cause superﬁcial as well as life-threatening systemic infec-
tions, especially in immunocompromised patients [1]. In-
fections by C. albicans are commonly treated with the
antimycotic agent ﬂuconazole that inhibits the biosynthesis
of ergosterol, the major sterol in the fungal cell membrane.
However, C. albicans can develop resistance to ﬂuconazole,
especially during long-term treatment of oropharyngeal
candidiasis, which frequently affects HIV-infected persons
and AIDS patients [2]. Molecular ﬁngerprinting of serial C.
albicans isolates from recurrent episodes of oropharyngeal
candidiasis has shown that ﬂuconazole resistance usually
develops in previously susceptible strains, and such serial
isolates from the same patient, so-called matched isolates,
have proved an excellent tool to study the molecular basis of
drug resistance [3–10]. Fluconazole resistance can be caused
by different mechanisms, including alterations in the sterol
biosynthetic pathway, increased expression of the ERG11
gene that encodes the target enzyme of ﬂuconazole, sterol
14a-demethylase (Erg11p), mutations in the ERG11 gene that
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overexpression of genes encoding membrane transport
proteins, which transport ﬂuconazole out of the cell. In
clinical C. albicans strains, several of these mechanisms are
often combined to result in a stepwise development of
clinically relevant ﬂuconazole resistance (for a review, see
[11]).
A major mechanism of drug resistance in C. albicans is the
constitutive upregulation of genes encoding efﬂux pumps that
actively transport ﬂuconazole and many other, structurally
unrelated toxic compounds out of the cell. Two types of efﬂux
pumps have been identiﬁed in C. albicans [12–15]. The CDR1
and CDR2 genes encode ATP-binding cassette (ABC) trans-
porters, whereas MDR1 encodes a multidrugefﬂuxpumpofthe
major facilitator superfamily. In drug-susceptible C. albicans
strains, MDR1 is expressed at low or non-detectable levels in
standard laboratory media, but its expression can be induced
when the cells are grown in the presence of certain toxic
compounds, like benomyl, hydrogen peroxide, or diamide [16–
20]. In contrast, many ﬂuconazole-resistant, clinical C. albicans
isolates constitutively overexpress MDR1 [3,4,7–10]. Inactiva-
tion of MDR1 in such MDR1 overexpressing C. albicans isolates
increased their susceptibility to ﬂuconazole, conﬁrming that
MDR1 overexpression contributed to ﬂuconazole resistance
[21]. The increased resistance of such isolates to other
metabolic inhibitors, like cerulenin, brefeldin A, and diamide
was completely abolished after MDR1 deletion, indicating that
the resistance of the strains to these toxic compounds was
mainly or exclusively mediated by Mdr1p [22,23]. Comparison
of the MDR1 promoter sequences in matched pairs of
ﬂuconazole-susceptible and MDR1 overexpressing, ﬂucona-
zole-resistant C. albicans isolates from the same patient
demonstrated that the constitutive MDR1 upregulation in the
resistant isolates was not caused by promoter mutations but by
alterationsintrans-regulatoryfactor(s)[24].Severalgroupshave
identiﬁed sequences in the MDR1 promoter region that
mediate its upregulation in drug-sensitive strains in response
to inducing chemicals and its constitutive activation in drug-
resistant strains [19,20,25,26]. However, in contrast to the ABC
transporters CDR1 and CDR2, whose expression has recently
been shown to be controlled by the transcription factor Tac1p,
which is mutated in CDR1/CDR2 overexpressing C. albicans
strains [27,28], the regulatory factors controlling MDR1
expression and the mutations that are responsible for its
constitutive overexpression in drug-resistant clinical isolates
have not yet been identiﬁed.
In this study, we compared the alterations in gene
expression occurring in three different MDR1 overexpress-
ing, clinical C. albicans isolates on a genome-wide scale to
identify genes that are commonly upregulated with MDR1.
This approach led to the identiﬁcation of a central regulator
of MDR1 expression and to the elucidation of the molecular
basis of MDR1 overexpression and multidrug resistance in
clinical C. albicans isolates.
Results
Expression of the Transcription Factor MRR1 Is
Coordinately Upregulated with MDR1 in Drug-Resistant,
Clinical C. albicans Isolates
To identify genes that are coordinately upregulated with
MDR1, we compared the transcriptional proﬁles of three
matched pairs of ﬂuconazole-susceptible and ﬂuconazole-
resistant clinical C. albicans isolates. F1 and G1 are the ﬁrst,
drug-susceptible isolates of two well-characterized series of
clinical C. albicans isolates and do not detectably express
MDR1, while F5 and G5 are the last isolates in each series that
overexpress MDR1 and have become multidrug-resistant
[8,21,23,24]. An additional isolate pair from another patient,
isolates 5833 (no MDR1 expression) and 6692 (MDR1 over-
expression), was obtained from Martine Raymond and has
been described recently [29]. As can be seen in Figure 1, a
common set of 21 genes was consistently upregulated in all
three MDR1 overexpressing isolates, including all the genes
encoding proteins that had previously been identiﬁed as
upregulated in isolates F5 and G5 by proteome analysis [23].
In addition, seven genes were downregulated in all resistant
isolates. The complete data set for all differentially expressed
genes in the pairwise comparisons can be found in Table S1.
Interestingly, one gene, orf19.7372 (IPF1266), which was
moderately upregulated in the MDR1 overexpressing strains,
encodes a predicted zinc cluster transcription factor that has
been given the preliminary name ZCF36 in the Candida
Genome Database (http://www.candidagenome.org/). As tran-
scription factors often regulate their own expression in
addition to that of their target genes, we hypothesized that
this transcription factor might be involved in MDR1
expression and thereby control multidrug resistance. The
results shown below demonstrate that this was indeed the case
and we have therefore named orf19.7372 as MRR1, for
multidrug resistance regulator.
Inactivation of MRR1 Abolishes Multidrug Resistance of
MDR1 Overexpressing C. albicans Strains
To investigate if MRR1 affects drug resistance in C. albicans,
we deleted the gene in the C. albicans model strain SC5314 as
well as in the drug-resistant clinical isolates F5 and G5 using
the SAT1-ﬂipping strategy ([30], Figure 2A and 2C, lanes 1–3,
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Author Summary
The Candida albicans MDR1 (multidrug resistance) gene encodes a
multidrug efflux pump of the major facilitator superfamily that is
constitutively overexpressed in many fluconazole-resistant strains.
Although MDR1 overexpression is a major cause of resistance to this
widely used antifungal agent and other metabolic inhibitors, so far
the molecular basis of MDR1 upregulation in resistant strains has
remained elusive. By comparing the transcription profiles of MDR1
overexpressing, clinical C. albicans isolates and matched, drug-
susceptible isolates from the same patients, we identified a
transcription factor, termed multidrug resistance regulator 1
(MRR1), which was upregulated in all resistant isolates and turned
out to be a central regulator of MDR1 expression. Resistant isolates
contained point mutations in MRR1, which rendered the tran-
scription factor constitutively active. Introduction of these mutated
alleles into a susceptible strain caused MDR1 overexpression und
multidrug resistance. Inactivation of MRR1 in clinical isolates
abolished MDR1 expression and affected fluconazole resistance
even more strongly than deletion of the MDR1 efflux pump itself,
indicating that additional Mrr1p target genes, which were identified
by genome-wide gene expression analysis, contribute to fluconazole
resistance. These findings provide detailed insights into the
molecular basis of multidrug resistance in one of the most
important human fungal pathogens.and unpublished data). From each parental strain, two
independent homozygous mrr1D mutants were constructed
(see Table S2) and tested for their susceptibilities to various
metabolic inhibitors to which MDR1 overexpression confers
resistance [22,23,31]. Inactivation of MRR1 in the drug-
susceptible strain SC5314, which does not detectably express
MDR1 under standard growth conditions, did not affect its
susceptibility to the tested compounds, except for diamide,
which is known to induce MDR1 expression (see also below).
In contrast, the mrr1D mutants of the MDR1 overexpressing
isolates F5 and G5 completely lost their resistance to
cerulenin, brefeldin A, and diamide and became as suscep-
tible to these inhibitors as mdr1D mutants derived from these
strains or the matched, drug-susceptible isolates F2 and G2,
Figure 1. Identification of Genes that Are Differentially Expressed in MDR1 Overexpressing Clinical C. albicans Isolates
(A, B) Venn Diagrams showing the number of genes that are upregulated (A) or downregulated (B) in the MDR1 overexpressing, drug-resistant isolates
F5, G5, and 6692 as compared with their matched drug-susceptible isolates F1, G1, and 5833, respectively.
(C) Heat map showing genes that are upregulated (red) or downregulated (green) in all three MDR1 overexpressing isolates. Results are from three
independent experiments (Exp. 1 to Exp. 3) for each comparison. The genes are ordered according to their relative degree of up- and downregulation,
as indicated by the brightness of the red and green fields (see Table S1 for details about the expression data). Gene names were taken from CandidaDB
(http://genolist.pasteur.fr/CandidaDB), except for MDR1 and MRR1, and their orf19 names are given.
doi:10.1371/journal.ppat.0030164.g001
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detectably express MDR1 [8] (Figure 3). The heterozygous
mrr1 mutants exhibited intermediate resistance. Resistance of
isolates F5 and G5 to these compounds was mediated mostly
or exclusively by MDR1 overexpression, since resistance was
lost after deletion of MDR1 [22,23]. In contrast, MDR1
overexpression contributes only partially to ﬂuconazole
resistance of these isolates, which is caused by a combination
of different mechanisms [8,21]. Interestingly, deletion of
MRR1 in isolates F5 and G5 had an even stronger effect than
inactivation of MDR1, suggesting that MRR1 is required for
various mechanisms of ﬂuconazole resistance. The increased
ﬂuconazole resistance of isolate F5 as compared with isolate
F2 was completely lost in the mrr1D mutants derived from this
strain, while the mrr1D mutants of isolate G5, which also
contains a mutation in the ERG11 gene that results in
reduced afﬁnity of ﬂuconazole for its target enzyme, were still
more resistant than the matched isolate G2, which does not
contain this mutation [8].
MRR1 Mediates Constitutive MDR1 Overexpression as well
as Inducible MDR1 Expression
The results presented above suggested that MRR1 affects
drug resistance by controlling expression of the MDR1 efﬂux
pump. Therefore, we compared MDR1 promoter activity in
the mrr1D mutants and their wild-type parental strains. For
this purpose, a PMDR1-GFP (green ﬂuorescent protein)
reporter fusion from plasmid pMPG2S (see Materials and
Methods) was integrated into the genome of these strains, and
GFP expression was quantiﬁed by ﬂow cytometry. As can be
seen in Figure 4A, the strong MDR1 promoter activity in
isolates F5 and G5 was completely abolished after deletion of
MRR1, demonstrating that MRR1 is required for the
constitutive activation of the MDR1 promoter in these
clinical isolates. The heterozygous MRR1/mrr1D mutants
exhibited reduced MDR1 promoter activity, showing that
both MRR1 alleles contributed to MDR1 overexpression in
the drug-resistant isolates. The loss of MDR1 expression in
the mrr1D mutants was also independently conﬁrmed by
quantitative real-time reverse transcription (RT)-PCR (see
Figure S1A).
As mentioned above, strain SC5314 does not detectably
express MDR1, and no signiﬁcant MDR1 promoter activity
was seen in the corresponding reporter strains (Figure 4B).
However, MDR1 expression can be induced in drug-suscep-
tible strains when the cells are exposed to certain chemicals
[16–19]. We used two such compounds, benomyl and H2O2,t o
investigate whether MRR1 is also required for inducible
MDR1 expression. These chemicals were chosen because it
has recently been reported that different regions in the
MDR1 promoter mediate its upregulation by benomyl and
Figure 2. Construction of mrr1D Mutants and Complemented Strains
(A) Structure of the deletion cassette from plasmid pZCF36M2 (top),
which was used to delete the MRR1 ORF in strains SC5314, F5, G5, and
CAG48B, and genomic structure of the MRR1 locus in the parental
strains (bottom). The MRR1 coding region is represented by the white
arrow and the upstream and downstream regions (59MRR1 and 39MRR1)
by the solid lines. The SAT1 flipper cassette (SAT1-FLIP), in which the
caFLP gene is expressed from the inducible SAP2 promoter [30], is
represented by the grey rectangle bordered by FRT sites (black arrows).
The 34 bp FRT sites are not drawn to scale. The probes used for
Southern hybridization analysis of the mutants are indicated by the
black bars.
(B) Structure of the DNA fragments from plasmids pZCF36K2, pZCF36K3,
pZCF36K4, and pZCF36K5 (top), which were used for integration
the MRR1
F2–1, MRR1
F5, MRR1
G2–2, and MRR1
G5 alleles, respectively, into
the disrupted mrr1 locus of homozygous and heterozygous mrr1D
mutants (bottom) using the caSAT1 selection marker (grey arrow). TACT1,
transcription termination sequence of the ACT1 gene.
Only relevant restriction sites are given in (A) and (B): A, ApaI; B, BglII; E,
EcoRI; N, NsiI; Nd, NdeI; P, PstI; S, SalI; ScI, SacI; ScII, SacII; X, XhoI. The PstI
and NsiI sites shown in parenthesis were destroyed by the cloning
procedure.
(C) Southern hybridization of NsiI-digested genomic DNA of mrr1D
mutants derived from strain SC5314 and of strains with reinserted MRR1
alleles with the MRR1-specific probe 1. The sizes of the hybridizing
fragments (in kb) are given on the left side of the blot and their identities
are indicated on the right. The genotype of the strains is given above the
respective lanes. Only one of the two independently constructed series
of strains is shown. Inactivation of MRR1 in the clinical isolates F5 and G5
and the reporter strain CAG48B and reinsertion of different MRR1 alleles
in mrr1 mutants of the reporter strain occurred in an analogous fashion.
doi:10.1371/journal.ppat.0030164.g002
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effect on MDR1 promoter activity under these conditions,
activation of the MDR1 promoter by either of the two
compounds was almost completely abolished in the homo-
zygous mrr1D mutants (Figure 4B). Therefore, MRR1 is
required for both the constitutive MDR1 overexpression in
drug-resistant, clinical C. albicans isolates and the inducible
MDR1 expression in a drug-susceptible strain.
The Drug-Resistant, Clinical C. albicans Isolates F5 and G5
Contain Mutated MRR1 Alleles
Since MRR1 was upregulated in the MDR1 overexpressing
clinical C. albicans isolates, we investigated whether artiﬁcial
overexpression of MRR1 would result in activation of the
MDR1 promoter. For this purpose, we placed the MRR1
coding region from strain SC5314 under the control of the
strong ADH1 promoter in plasmid pZCF36E1 (see Materials
and Methods). The PADH1-MRR1 fusion was integrated into
strain CAG48B, a derivative of the ﬂuconazole-sensitive
laboratory strain CAI4, which expresses the GFP reporter
gene from the endogenous MDR1 promoter (see Table S2).
The resulting strain did not detectably express the GFP gene,
similar to a control strain that carried an otherwise identical
construct without the MRR1 gene (unpublished data),
suggesting that overexpression of MRR1 was not sufﬁcient
to activate the MDR1 promoter and that the drug-resistant
isolates F5 and G5 might carry gain-of-function mutations in
MRR1. Therefore, we cloned and sequenced the MRR1 alleles
of isolates F2, F5, G2, and G5 (see Table S3). Isolate F2
contained two polymorphic MRR1 alleles. The coding region
of allele 1 (MRR1
F2–1) was identical to the MRR1 sequence of
strain SC5314, while allele 2 (MRR1
F2–2) differed from it at 26
positions, with three of the polymorphisms resulting in amino
acid exchanges. Only one allele (MRR1
F5) was obtained from
the matched resistant isolate F5 and this allele corresponded
to allele 1 of isolate F2 except for a single C-T mutation at
position 2047, which resulted in a proline-serine substitution
at position 683 of Mrr1p. Direct sequencing of the PCR
Figure 3. MRR1 Mediates Drug Resistance of MDR1 Overexpressing Clinical C. albicans Isolates
Minimal inhibitory concentration (MIC) of the indicated metabolic inhibitors (in lgm l
 1) for the drug-sensitive clinical isolates F2 and G2, the matched
drug-resistant isolates F5 and G5, and two independently constructed heterozygous and homozygous mrr1D mutants as well as mdr1D mutants of the
drug-resistant isolates F5 and G5. The susceptibilities of the isolates F2, F5, and its mutant derivatives are shown in the left panels, and those of isolates
G2, G5, and its mutant derivatives are shown in the right panels.
doi:10.1371/journal.ppat.0030164.g003
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and the absence of the mutation in the MRR1 alleles of isolate
F2. A similar situation was found for the isolate pair G2/G5.
Isolate G2 contained two polymorphic MRR1 alleles
(MRR1
G2–1 and MRR1
G2–2), which differed from one another
at 28 positions, with two of the polymorphisms resulting in
amino acid differences. G5 contained only one MRR1 allele
(MRR1
G5) that was identical with allele 2 of isolate G2 except
for a single G-T mutation at position 2990, which resulted in
a glycine–valine substitution at position 997 of Mrr1p.
Therefore, both resistant isolates F5 and G5 had become
homozygous for a mutated MRR1 allele, suggesting that these
mutations might have caused the constitutive MDR1 over-
expression and the resulting multidrug resistance.
MDR1 Overexpression and Multidrug Resistance in Clinical
C. albicans Isolates Are Caused by Gain-of-Function
Mutations in MRR1
To directly test whether the P683S and G997V mutations in
Mrr1p are responsible for MDR1 overexpression and drug
resistance, we introduced the mutated MRR1 alleles from
isolates F5 and G5 as well as the corresponding wild-type
alleles from isolates F2 and G2 into the mrr1D mutants of
strain SC5314. All four MRR1 alleles were integrated into one
of the inactivated mrr1D alleles to ensure expression from the
endogenous MRR1 promoter (see Figure 2B and 2C, lanes 4–
7). In each case, two independent correct transformants were
used for further analysis. Figure 5A shows that, as noted
above, deletion of MRR1 in strain SC5314 did not affect its
susceptibility to cerulenin, brefeldin A, and ﬂuconazole, but
the mutants displayed increased sensitivity to diamide, a
Figure 4. MRR1 Is Required for Constitutive and Induced MDR1 Expression
(A) Constitutive MDR1 promoter activity in the drug-resistant clinical
isolates F5 and G5 and in heterozygous and homozygous mrr1D
mutants. The mean fluorescence of two independently constructed
derivatives of each parental strain carrying a PMDR1-GFP reporter fusion
and grown to log phase in YPD medium was determined by flow
cytometry. The parental strains F5 and G5, which do not contain the GFP
gene, were included as negative controls.
(B) Benomyl- and H2O2-induced MDR1 promoter activity in strain SC5314
andits mrr1D derivatives. Two independently constructedreporterstrains
of eachparentalstrain carrying a PMDR1-GFP reporterfusion were grown in
the absence (-) or presence (þ) of benomyl or H2O2 as detailed in the
experimental procedures and the mean fluorescence of the cells was
determined by flow cytometry. The parental strain SC5314, which does
not contain GFP, was included to control for background fluorescence.
doi:10.1371/journal.ppat.0030164.g004
Figure 5. MRR1 Gain-of-Function Alleles Cause Constitutive MDR1
Overexpression and Multidrug Resistance
(A) MICs (in lgm l
 1) of the indicated metabolic inhibitors for the wild-
type parental strain SC5314, two independently constructed homozy-
gous mrr1D mutants, and derivatives carrying the indicated mutant
MRR1 alleles in the absence or presence of a wild-type MRR1 allele.
(B) MDR1 promoter activity in a wild-type reporter strain, an mrr1D
mutant, and derivatives carrying the indicated mutant MRR1 alleles in the
absence or presence of a wild-type MRR1 allele. The strains were grown
to log phase in YPD medium and the mean fluorescence of the cells was
determined by flow cytometry.
doi:10.1371/journal.ppat.0030164.g005
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substrate. Insertion of the MRR1–1 allele from isolate F2
(which is identical to MRR1 of strain SC5314, so this also
represented a reinsertion of the original allele) or the MRR1–
2 allele from isolate G2 complemented the hypersuscepti-
bility of the mutants to diamide, but did not increase
resistance to cerulenin, brefeldin A, and ﬂuconazole. In
contrast, insertion of the mutated alleles from isolates F5 and
G5 resulted in enhanced resistance to all compounds. To
obtain direct evidence that the mutated MRR1 alleles confer
drug resistance by activating the MDR1 promoter and, thus,
mediate overexpression of the Mdr1p efﬂux pump, we
integrated the various MRR1 alleles into a derivative of the
laboratory strain CAI4 that expresses the GFP reporter gene
from the endogenous MDR1 promoter. For this purpose, we
ﬁrst inactivated the MRR1 wild-type alleles in the reporter
strain CAG48B, as described above for the other strains, and
then reinserted one of the four different MRR1 alleles. Two
independent transformants were kept for each MRR1 allele.
Figure 5B shows that, while the MRR1
F2–1 and MRR1
G2–2
alleles from the susceptible isolates had no effect, expression
of the corresponding mutated MRR1
F5 and MRR1
G5 alleles
resulted in strong MDR1 promoter activity. MDR1 upregu-
lation by the mutated MRR1 alleles was also independently
conﬁrmed by comparing MDR1 mRNA levels in strains
carrying wild-type or mutated MRR1 alleles by quantitative
real-time RT-PCR (see Figure S1B). These results demon-
strated that the P683S and G997V mutations in Mrr1p caused
constitutive MDR1 overexpression and multidrug resistance.
MRR1 Gain-of-Function Alleles Mediate MDR1
Overexpression and Multidrug Resistance in a Semi-
Dominant Fashion
A mutation in the transcription factor TAC1 has recently
been shown to cause constitutive upregulation of the ABC-
transporters CDR1 and CDR2 as well as drug resistance in
certain C. albicans strains, but only after the strains had
become homozygous for the mutated allele [28]. Since the
resistant isolates F5 and G5 also had become homozygous for
mutated MRR1 alleles, we tested whether these alleles could
mediate MDR1 overexpression and drug resistance in the
presence of a non-mutated, wild-type allele. Therefore, to
produce strains that contained both a wild-type and a
mutated allele, the MRR1 alleles from isolates F5 and G5
were inserted into the inactivated mrr1 allele in the
heterozygous MRR1/mrr1D mutants derived from strain
SC5314 (see Figure 2B and 2C, lanes 8 and 9). The mutated
alleles conferred drug resistance also in the presence of a
wild-type MRR1 allele, although we observed a slightly
reduced resistance as compared with the strains containing
only a mutated MRR1 allele, especially for the MRR1
F5 allele
(see Figure 5A). To directly compare MDR1 promoter activity
in strains carrying only a mutated MRR1 allele or both a
mutated and a wild-type MRR1 allele, the mutated MRR1
alleles were also integrated into the inactivated mrr1 allele of
the heterozygous MRR1/mrr1D mutant with the PMDR1-GFP
reporter fusion. Figure 5B shows that both mutated MRR1
alleles were able to activate the MDR1 promoter in the
presence of a wild-type MRR1 allele, but the degree of
activation was lower than in strains containing only a
mutated allele. Again, this effect was more pronounced for
the MRR1
F5 allele. Taken together, these results demonstrate
that the MRR1
F5 and MRR1
G5 alleles can act in a semi-
dominant fashion and mediate MDR1 overexpression and
multidrug resistance in the presence of a nonmutated MRR1
allele, but the presence of a wild-type MRR1 allele reduces
the activity of the MRR1 alleles containing gain-of-function
mutations.
Identification of Mrr1p Target Genes
That deletion of MRR1 from the drug-resistant C. albicans
isolates F5 and G5 affected ﬂuconazole resistance more
strongly than deletion of MDR1 suggests that Mrr1p controls
the expression of additional genes that contribute to the
increased ﬂuconazole resistance of these isolates. Therefore,
to identify the set of genes controlled by the transcription
factor Mrr1p, we compared the gene expression proﬁles of
isogenic strains expressing either a wild-type MRR1 allele
(MRR1
F2–1 or MRR1
G2–2) or its constitutively active, mutated
counterpart (MRR1
F5 and MRR1
G5, respectively). In addition,
we compared the gene expression proﬁles of the clinical
isolates F5 and G5, which carry the gain-of-function MRR1
alleles, with those of their mrr1D derivatives.
As shown in Figure 6A and 6B, 20 and 27 genes were
consistently upregulated in the transformants expressing the
MRR1
F5 and MRR1
G5 alleles, respectively, and 19 of the 28
total genes were commonly upregulated by both gain-of-
function alleles. As expected, CDR1 and CDR2 were not
among the Mrr1p target genes. Strikingly, the 11 most
strongly upregulated genes were the same in strains express-
ing the MRR1
F5 or the MRR1
G5 allele. All of these (plus three
additional commonly upregulated genes) were also signiﬁ-
cantly overexpressed in the drug-resistant clinical isolates F5
and G5 as compared with the matched susceptible isolates F1
and G1, respectively, and downregulated again after deletion
of MRR1 from the resistant isolates F5 and G5. These 14
genes, therefore, represent a core set of genes whose
expression is controlled by Mrr1p, and some of them might
contribute to ﬂuconazole resistance in the clinical isolates
(see Discussion).
Twenty-eight genes (including MRR1) were consistently
downregulated after deletion of MRR1 in the resistant
isolates F5 and G5 (see Table 1) A complete list of all genes
that were found to be differentially regulated in the mrr1D
mutants as compared with their wild-type parental strains is
provided in Table S4. Fourteen of the 28 genes were also
upregulated by the MRR1
F5 and MRR1
G5 alleles in the
SC5314 background and in the resistant isolates F5 and G5 as
compared with the matched susceptible isolates F1 and G1,
respectively. The 14 genes were mainly those most strongly
affected by the MRR1 deletion. The other genes were either
not consistently upregulated above the threshold level in the
SC5314 transformants expressing only one mutated MRR1
allele (e.g., MRR1 itself) or possibly had a strain-speciﬁc
dependence on MRR1.
Altogether, the results of the transcriptional proﬁling
experiments provided a comprehensive list of genes that
are regulated, directly or indirectly, by Mrr1p in various C.
albicans strain backgrounds. The identiﬁcation of these genes,
in turn, provided clues about how gain-of-function mutations
in MRR1 contribute to ﬂuconazole resistance of clinical C.
albicans strains, besides causing overexpression of the MDR1
efﬂux pump (see Discussion).
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Since the initial report by Sanglard et al. more than ten
years ago [3], many studies have shown that the major
mechanism of resistance to the widely used antifungal agent
ﬂuconazole in clinical C. albicans isolates is the constitutive
overexpression of efﬂux pumps, which actively transport this
drug and other toxic substances out of the cell, thereby
conferring multidrug resistance. It is well established that
mutations in trans-regulatory factors are responsible for the
upregulation of genes encoding efﬂux pumps in drug-
resistant C. albicans isolates [24,32]; however, until recently
the identity of these regulators has remained elusive. Two
main factors, namely 1) the discovery of a cis-regulatory
element in the promoters of CDR1 and CDR2 with features
that are typical of binding sites of zinc cluster transcription
factors, and 2) the observation that homozygosity at the
mating type locus was linked with the development of azole
resistance in certain clinical strains, led Coste et al. to exploit
the available C. albicans genome sequence information to
systematically search for candidate transcription factors that
might regulate the expression of these efﬂux pumps. This
strategy resulted in the identiﬁcation of the zinc cluster
transcription factor TAC1, which is located near the mating
type locus, as the major regulator of CDR1 and CDR2 [27]. In
contrast, no obvious criteria for a similar in silico search for a
regulator of MDR1, the other efﬂux pump that mediates drug
resistance in many clinical C. albicans isolates, were evident.
Promoter deletion analyses performed by several research
groups have identiﬁed three different activating regions in
the MDR1 promoter, two of which contain binding sites for
the transcription factors Cap1p and Mcm1p [19,20,25,26].
However, each of these regions could be individually deleted
from the full-length MDR1 promoter without abrogating its
constitutive activation in MDR1 overexpressing C. albicans
isolates, which suggested that a transcription factor other
than Cap1p or Mcm1p causes the upregulation of MDR1 in
drug-resistant strains. Assuming that a common mechanism
might be responsible for the constitutive MDR1 upregulation
in such strains, we compared the alterations in gene
expression that occurred in three different MDR1 over-
expressing, drug-resistant C. albicans isolates. This approach
led to the identiﬁcation of MRR1, a zinc cluster transcription
factor that was moderately upregulated in all three resistant
isolates as compared with matched, drug-susceptible isolates,
suggesting that this transcription factor might contribute to
MDR1 overexpression and/or drug resistance. A role of MRR1
in ﬂuconazole resistance would not have been easily inferred
from genetic analysis of commonly used C. albicans laboratory
strains, because deletion of MRR1 from the model strain
SC5314 did not result in hypersusceptibility of the mutants.
However, the development of methods to inactivate genes in
clinical C. albicans strains [21,30] allowed us to demonstrate
the essential role of MRR1 in drug resistance of two different
MDR1 overexpressing C. albicans isolates. Similar ﬁndings
were previously obtained with the efﬂux pump MDR1 itself,
whose disruption in a C. albicans laboratory strain did not
result in ﬂuconazole hypersusceptibility, whereas MDR1
inactivation in MDR1 overexpressing strains reduced or
abolished their resistance to ﬂuconazole and other metabolic
inhibitors [14,21,33]. We found that MRR1 is not only
responsible for the constitutive overexpression of MDR1 in
drug-resistant isolates, but also mediates the inducible MDR1
expression in a drug-susceptible strain. The transcription
factors Cap1p and Mcm1p have been implicated in the
induction of MDR1 expression by H2O2 and benomyl,
respectively [20]. Interestingly, deletion of MRR1 almost
completely abolished the induction of the MDR1 promoter in
response to both of these stimuli, indicating that Mrr1p has a
more central and essential role in the control of MDR1
expression and, depending on the environmental conditions,
may cooperate in different ways with these other tran-
scription factors to regulate expression of the efﬂux pump.
The identiﬁcation of MRR1 as the central regulator of
MDR1 expression also enabled us to elucidate the genetic
alterations that had occurred in drug-resistant C. albicans
isolates and were responsible for MDR1 overexpression and
multidrug resistance. In two clinical isolates we found
different single nucleotide substitutions in MRR1 that
resulted in amino acid exchanges in Mrr1p. The ability of
the mutated MRR1 alleles to activate the MDR1 promoter
and confer drug resistance when expressed in a C. albicans
laboratory strain conﬁrmed that these were indeed gain-of-
function mutations that resulted in constitutive activation of
the transcription factor. The two mutations, which were
found in different regions of Mrr1p, most likely relieve the
transcription factor from repression by an autoinhibitory
domain or by another negatively acting factor that keeps
Mrr1p in its inactive state in the absence of inducing signals.
In both cases the MDR1 overexpressing, drug-resistant isolate
had become homozygous for the mutated MRR1 allele, which
suggested that Mrr1p containing a gain-of-function mutation
would not be able to activate the MDR1 promoter in the
presence of wild-type Mrr1p. However, we found that both
mutated MRR1 alleles were able to induce MDR1 expression
and cause drug resistance in the presence of a wild-type allele,
albeit at slightly reduced levels as compared with strains
containing only the mutated allele. This indicates that the
Figure 6. Identification of Mrr1p Target Genes by DNA Microarray Analysis
(A) Genes that were upregulated by the P683S mutation in the SC5314 genetic background (MRR1
F5 versus MRR1
F2–1). The genes are ordered according
to their average degree of upregulation in four repeat experiments performed with two independent transformants (strains A and B). The changes in
the expression level of these genes in the drug-resistant clinical isolate F5 as compared with a matched susceptible isolate (F5 versus F1) and in two
independently constructed mrr1D mutants (strains A and B) as compared with their wild-type progenitor F5 (F5mrr1D versus F5) are shown for
comparison.
(B) Genes that were upregulated by the G997V mutation in the SC5314 genetic background (MRR1
G5 versus MRR1
G2–2). The genes are ordered
according to their average degree of upregulation in four repeat experiments performed with two independent transformants (strains A and B). The
changes in the expression level of these genes in the drug-resistant clinical isolate G5 as compared with a matched susceptible isolate (G5 versus G1)
and in two independently constructed mrr1D mutants (strains A and B) as compared with their wild-type progenitor G5 (mrr1D versus G5) are shown for
comparison.
The fold increase or decrease in the expression of the genes is given for each experiment. Upregulated genes are highlighted in red, downregulated
genes are highlighted in green, and genes that were not differentially expressed are shown as white boxes in all pairwise comparisons.
doi:10.1371/journal.ppat.0030164.g006
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The comparison of heterozygous and homozygous mrr1D
mutants with their drug-resistant parental strains showed
that the presence of two rather than only one mutated MRR1
allele resulted in higher MDR1 promoter activity and drug
resistance. Therefore, the increased activity of the tran-
scription factor in strains carrying two copies of a mutated
MRR1 allele instead of only one, coupled with a slight
negative effect of wild-type Mrr1p on the activity of the
activated form, appears to provide sufﬁcient advantage
during antimycotic therapy to select for the loss of hetero-
zygosity once a gain-of-function mutation has occurred in
one of the two MRR1 alleles. Such a loss of heterozygosity
readily occurs in C. albicans either by loss of one chromosome
and duplication of the homologous chromosome or by
mitotic recombination between the two homologous chro-
mosomes, as has been well documented in several recent
studies [28,34,35].
Interestingly, deletion of the transcription factor MRR1
from MDR1 overexpressing C. albicans isolates reduced
ﬂuconazole resistance of these strains even more than
deletion of MDR1 itself, suggesting that the gain-of-function
mutations in MRR1 contribute to ﬂuconazole resistance of
these strains by other mechanisms, in addition to causing
overexpression of the efﬂux pump. We, therefore, aimed to
ﬁnd out which of the many alterations in gene expression
seen in the drug-resistant C. albicans clinical isolates (see
Figure 1 and Table S1) were caused by the MRR1 mutations.
When introduced into strain SC5314, both mutated MRR1
alleles caused the upregulation of 19 genes including MDR1
(note that some genes of the IFD family may in fact be alleles
of the same gene, e.g., those that were originally designated as
IFD1 and IFD5 in CandidaDB but have now been assigned the
same orf19 name). Some additional genes were reproducibly
upregulated by only one of the two mutated alleles (one for
MRR1
F5 and eight for MRR1
G5), which could be explained by
differential effects of the P683S and G997V mutations on
Mrr1p activity at the respective target promoters. The
expression of 14 of the 19 genes that were upregulated by
both mutated MRR1 alleles in the SC5314 background was
found to be downregulated after deletion of MRR1 in both
drug-resistant clinical isolates F5 and G5. A considerable
number of additional genes were affected by inactivation of
MRR1 in the clinical isolates (see Table S4), but only 28 genes
were downregulated in the mrr1D mutants of both parental
Table 1. Genes Commonly Downregulated by MRR1 Deletion in Isolates F5 and G5
Gene
a orf19 Number S. cerevisiae
Orthologue or
Best Hit
b
Gene Ontology annotation
(Molecular Function)/Description
c
Fold Downregulation in mrr1D
Mutants of Isolates
F5 G5
IPF9538 orf19.271 YMR226C 2,4-dienoyl-CoA reductase (NADPH) activity  282.4  17.7
MDR1 orf19.5604 FLR1 Multidrug transporter activity  46.9  126.3
MRR1 orf19.7372 HAP1 Specific RNA polymerase II transcription factor activity  50.7  44.7
IFD6 orf19.4476 YPL088W Aryl-alcohol dehydrogenase activity  30.3  31.4
IFD5 orf19.1048 YPL088W Aryl-alcohol dehydrogenase activity  13.2  4.0
IPF5987 orf19.7306 YPR127W Protein of aldo-keto reductase family  7.4  9.8
IPF17186 orf19.251 HSP31 Cysteine-type peptidase activity  9.2  7.0
IPF7863 orf19.1449 YFL061W Protein whose expression is induced by DNA damage  11.8  3.7
IFD7 orf19.629 YPL088W Aryl-alcohol dehydrogenase activity  6.7  8.1
HGT11 orf19.4527 HXT11 Glucose transmembrane transporter activity  5.1  5.9
HGT12 orf19.3668 RGT2 Glucose transmembrane transporter activity  3.3  7.2
IPF525 orf19.7085 — Induced in core stress response  6.2  2.4
IPF2186 orf19.7166 YGR110W Transcription is increased in response to genotoxic stress  3.4  4.9
IFK3 orf19.857 — Expression regulated during planctonic growth  4.6  3.0
IPF7817 orf19.3131 OYE3 NADPH dehydrogenase activity  4.4  3.0
IPF19538 orf19.6957.3 — —  2.0  5.4
IFD1 orf19.1048 YPL088W Aryl-alcohol dehydrogenase activity  2.6  4.6
IFD4 orf19.4477 YPL088W Aryl-alcohol dehydrogenase activity  2.9  3.7
AAF1 orf19.7436 — Possible regulatory protein involved in adhesion  3.1  3.4
FRE30.53 orf19.6140 FRE3 Ferric-chelate reductase activity  3.5  2.8
FRE30.3 orf19.6139 FRE3 Ferric-chelate reductase activity  3.2  2.9
IFD2 orf19.771 YPL088W Aryl-alcohol dehydrogenase activity  3.1  2.8
IPF1634 orf19.6578 PHO84 Inorganic phosphate transmembrane transporter activity  2.4  3.3
GRP2 orf19.4309 GRE2 Oxidoreductase activity  1.9  3.4
ARD8 orf19.6322 SPS19 2,4-dienoyl-CoA reductase (NADPH) activity  2.3  2.3
FRE7 orf19.7077 FRE7 Ferric-chelate reductase activity  2.2  2.2
GAP6 orf19.6659 GAP1 Amino acid transmembrane transporter activity  2.1  1.7
AKL1 orf19.5357 AKL1 Protein serine/threonine kinase activity  1.7  1.7
aGenes are listed according to their average degree of downregulation in mrr1D mutants in both strain backgrounds, in each case determined from four repeat experiments performed
with two independently constructed mutants (see Table S4). Genes that were also upregulated in the drug-resistant isolates as compared with their matched susceptible isolates (F5
versus F1 and G5 versus G1) and by MRR1 alleles containing gain-of-function mutations in the SC5314 background (MRR1
F5 versus MRR1
F2–1 and MRR1
G5 versus MRR1
G2–2) are highlighted
in bold letters.
bAccording to Candida Genome Database (http://www.candidagenome.org/).
cGene ontology terms and descriptions were taken from Candida Genome Database (http://www.candidagenome.org/) or Saccharomyces Genome Database (http://www.yeastgenome.
org/).
doi:10.1371/journal.ppat.0030164.t001
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depended on the strain background.
It is striking that of the core set of Mrr1p target genes (i.e.,
the 14 genes that were upregulated by the mutated MRR1
alleles in the SC5314 background as well as upregulated in the
drug-resistant isolates F5 and G5 and downregulated in the
mrr1D mutants of these strains) many encode putative
oxidoreductases (see Table 1). IPF7817 is a member of the
NAD(P)H oxidoreductase family that is strongly induced
during oxidative stress [36,37]. It is supposed to be involved in
the regulation of intracellular redox homeostasis, as mutants
in which the gene was inactivated had increased intracellular
levels of reactive oxygen species (ROS) and, presumably as a
compensatory mechanism, upregulated other redox-related
genes [38]. IPF17186 is a member of the ThiJ/PfpI protein
family [39]. Its ortholog in S. cerevisiae, also named HSP31,i s
induced by the transcription factor Yap1p in response to
oxidative stress. Also, an hsp31D mutant is hypersensitive to a
subset of ROS generators, suggesting that Hsp31p may
protect the cell against oxidative stress [40]. GRP2 is a
homolog of S. cerevisiae GRE2, which encodes a stress-induced
NADH-dependent methylglyoxal reductase that is regulated
by the pleiotropic drug resistance regulator Pdr1p. A gre2D
mutant exhibited a growth defect under conditions of
membrane stress and activated ERG genes as a compensatory
mechanism, and it displayed an increased sensitivity to
ergosterol biosynthesis inhibitors [41]. IFD1, IFD4, IFD5,
IFD6, and IFD7 encode proteins of the aldo-keto reductase
family and are homologs of the putative aryl-alcohol
dehydrogenase YPL088w of S. cerevisiae. Interestingly,
YPL088w is regulated by the transcriptional regulators Yrr1p
and Yrm1p, which are involved in the control of multidrug
resistance [42]. Similarly, IPF5987 encodes a member of the
aldo-keto reductase family, and its ortholog in S. cerevisiae is
also transcriptionally regulated by Yrr1p and Yrm1p [42].
MDR1 and other Mrr1p target genes, almost all of which
have also been found to be upregulated in another MDR1
overexpressing clinical C. albicans isolate [18], are induced in
the presence of chemicals that exert oxidative stress upon the
cells, like hydrogen peroxide or diamide. They are also
induced by the microtubule destabilizing agent benomyl
[16,18–20]. Interestingly, benomyl treatment causes lipid
peroxidation and glutathione depletion in rats and these
effects were blocked by treatment with antioxidants, suggest-
ing that the in vivo toxicity of benomyl may be associated
with oxidative stress to cellular membranes [43]. Therefore, it
seems possible that the activation of Mrr1p by all these
compounds may be a response to oxidative damage of the
cells, and the function of many of the target genes that are
induced by activated Mrr1p could be to restore the intra-
cellular redox balance. This may also explain how the
upregulation of these genes contributes to ﬂuconazole
resistance of clinical C. albicans strains containing MRR1
gain-of-function mutations. In addition to inhibiting ergo-
sterol biosynthesis, azoles have been shown to increase the
level of endogenous reactive oxygen species in C. albicans cells,
and the decrease in cell viability associated with miconazole
treatment was signiﬁcantly prevented by addition of an
antioxidant [44]. These observations suggest that ROS plays a
role in the mechanism of action of azole antifungal agents
and that ROS detoxiﬁcation mechanisms may contribute to
azole resistance. In contrast to other compounds that cause
oxidative stress, like hydrogen peroxide or diamide, ﬂucona-
zole does not induce MDR1 expression [8,16]. Therefore, the
constitutive upregulation of MDR1 and other Mrr1p target
genes in strains containing MRR1 gain-of-function mutations
provides protection of the cells against this antifungal agent.
A major regulator of the oxidative stress response in C.
albicans is the bZIP transcription factor Cap1p [36,45,46].
Like MDR1, several other Mrr1p target genes (IPF7817,
IPF17186, and GRP2) contain a YRE element, the putative
binding site for Cap1p, in their promoters. Their expression
is induced by hydrogen peroxide in a Cap1p-dependent
manner [18,20,36,45]. Therefore, Cap1p and Mrr1p may act
together to regulate expression of these genes in response to
oxidative stress. Cap1p also controls the expression of other
genes that are involved in the oxidative stress response, like
the thioredoxin reductase TRR1, the glutathione reductase
GLR1, the glutathione S-transferase GTT1, and the super-
oxide dismutase SOD2 [36,45], and which were not found
among the Mrr1p target genes. Unlike CAP1 inactivation [45],
MRR1 deletion or MRR1 gain-of-function mutations had no
effect on the susceptibility of C. albicans to H2O2 (unpub-
lished data), which in contrast to diamide is not a substrate of
the Mdr1p efﬂux pump [23]. Therefore, the Cap1p target
genes that are not controlled by Mrr1p and that are typical
oxidative stress-response genes seem to be more important
for the resistance of C. albicans to hydrogen peroxide, while
the Mrr1p target genes contribute to ﬂuconazole resistance,
presumably because the two compounds cause different
types of damage within the cells. The precise function of
most of the Mrr1p target genes is currently unknown and
their potential involvement in an oxidative stress response
remains speculative. Alternatively, it is possible that ﬂuco-
nazole treatment causes the accumulation of other toxic
molecules that are eliminated by the combined action of the
oxidoreductases and other gene products whose expression
is regulated by Mrr1p.
The identiﬁcation of MRR1 as the major regulator of
MDR1 expression and the elucidation of the mutations in
clinical isolates that cause constitutive activity of this tran-
scription factor represent a major step forward in our
understanding of multidrug resistance development in C.
albicans. Important questions that can now be addressed
include how Mrr1p is normally activated in response to
inducing signals, how gain-of-function mutations cause
constitutive activation of the transcription factor, and how
Mrr1p interacts with other putative MDR1 regulators like
Cap1p and Mcm1p to control expression of its target genes.
Materials and Methods
Strains and growth conditions. C. albicans strains used in this study
are listed in the supporting Table S2. All strains were stored as frozen
stocks with 15% glycerol at 80 8C. The strains were routinely grown
in YPD medium (10 g yeast extract, 20 g peptone, 20 g glucose per
liter) at 30 8C. To prepare solid media, 1.5% agar was added before
autoclaving. For induction of the MDR1 promoter with benomyl or
H2O2, overnight cultures of reporter strains were diluted 10
 2 in
three ﬂasks with fresh YPD medium and grown for 3 h. Fifty lg/ml of
benomyl or 0.005% H2O2 was then added to one of the cultures and
the cells were grown for an additional hour. The ﬂuorescence of the
cells was quantiﬁed by FACS analysis.
Plasmid constructions. The coding region of the MRR1 gene of C.
albicans strain SC5314 was ampliﬁed by PCR with the primers ZCF36–
1 and ZCF36–2 (primer sequences are given in Table S5). The PCR
product was digested at the introduced SalI and BglII restriction sites
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BglII-digested pOPT4E1 [47] to generate pZCF36E1. The sequence of
the cloned MRR1 gene was identical to that found in the genome
sequence of C. albicans strain SC5314 (orf19.7372). An MRR1 deletion
construct was generated in the following way: A SacI-SacII fragment
containing MRR1 upstream sequences from positions  314 to þ15
with respect to the start codon was ampliﬁed with the primers
ZCF36–3 and ZCF36–4, and an XhoI-ApaI fragment containing MRR1
downstream sequences from positions þ3260 to þ3557 was ampliﬁed
with the primers ZCF36–5 and ZCF36–6. The MRR1 upstream and
downstream fragments were cloned on both sides of the SAT1 ﬂipper
cassette in plasmid pSFS1 [30] to result in pZCF36M2 in which the
MRR1 coding region from positions þ16 to þ3259 (66 bp before the
stop codon) is replaced by the SAT1 ﬂipper (see Figure 2A). DNA
fragments containing the N-terminal part and upstream sequences of
the MRR1 alleles of the clinical C. albicans isolates F2, F5, G2, and G5
were ampliﬁed with the primers ZCF36–3 and ZCF36seq6, digested at
the introduced SacI site and at an internal EcoRI site, and cloned in
pBluescript to generate pZCF36NF2A and D, pZCF36NF5A,
pZCF36NG2B and D, and pZCF36G5A, respectively. DNA fragments
containing the MRR1 C-terminal part and downstream sequences
were ampliﬁed with the primers ZCF36–1 and ZCF36–6, digested at
the internal EcoRI site and at the introduced SacI site, and cloned in
pBluescript to obtain pZCF36CF2B and C, pZCF36CF5C,
pZCF36CG2A and D, and pZCF36CG5A, respectively. The complete
ORFs and upstream sequences of the MRR1–1 alleles of isolates F2
and G2 were also ampliﬁed with the primers ZCF36–3 and ZCF36–8
and cloned in pBluescript to yield pZCF36TF2–1 and pZCF36TG2–1,
respectively. To express wild-type and mutated MRR1 alleles in mrr1D
mutants, an EcoRI-SalI fragment from pZCF36E1 containing the C-
terminal part of MRR1,t h eACT1 transcription termination
sequence, and part of the caSAT1 selection marker was cloned into
the EcoRI/SalI-digested pZCF36NF2A to obtain pZCF36K1. An MRR1
downstream fragment was then ampliﬁed from SC5314 genomic DNA
with the primers ZCF36–7 and ZCF36–6, digested at the introduced
NsiI and ApaI sites, and cloned together with a BglII-PstI fragment
from pZCF36E1 containing the ACT1 transcription termination
sequence and the caSAT1 selection marker into the BglII/ApaI-
digested pZCF36K1 to generate pZCF36K2, which contains the
MRR1–1 allele of isolate F2 (which is identical to the MRR1 gene
of strain SC5314). Plasmid pZCF36K3, which contains the mutated
MRR1 allele from isolate F5, was obtained by substituting an EcoRI-
PstI fragment from pZCF36CF5C for the corresponding fragment in
pZCF36K2. For expression of the MRR1–2 allele of isolate G2, an
NdeI-EcoRI fragment from pZCF36NG2B and an EcoRI-PstI fragment
from pZCF36CG2D were substituted for the corresponding region in
pZCF36K2, resulting in pZCF36K4. Replacement of the EcoRI-PstI
fragment in this plasmid by the corresponding region from
pZCF36CG5A generated pZCF36K5, which contains the mutated
MRR1 allele from isolate G5. Plasmid pMPG2S, which contains a
PMDR1-GFP reporter fusion, was constructed by substituting the
caSAT1 selection marker from pSAT1 [30] for the URA3 marker in the
previously described plasmid pMPG2 [25].
C. albicans transformation. C. albicans strains were transformed by
electroporation [48] with gel-puriﬁed inserts from the plasmids
described above. Nourseothricin-resistant transformants were se-
lected on YPD agar plates containing 200 lg/ml nourseothricin
(Werner Bioagents) as described previously [30]. The correct genomic
integration of all constructs was conﬁrmed by Southern hybrid-
ization.
Isolation of genomic DNA and Southern hybridization. Genomic
DNA from C. albicans was isolated as described previously [49]. 10 lg
of DNA was digested with appropriate restriction enzymes, separated
on a 1% agarose gel and, after ethidium bromide staining, trans-
ferred by vacuum blotting onto a nylon membrane and ﬁxed by UV
cross-linking. Southern hybridization with enhanced chemilumines-
cence-labeled probes was performed with the Amersham ECL
TM
Direct Nucleic Acid Labeling and Detection System (GE Healthcare)
according to the instructions of the manufacturer.
Drug susceptibility tests. Stock solutions of the drugs were
prepared as follows. Fluconazole (1 mg/ml) and diamide (20 mg/ml)
were dissolved in water, while cerulenin (5 mg/ml) and brefeldin A (5
mg/ml) were dissolved in DMSO. In the assays, serial 2-fold dilutions
in the assay medium were prepared from the following initial
concentrations: cerulenin, 200 lg/ml; brefeldin A, 200 lg/ml; diamide,
800 lg/ml; ﬂuconazole, 200 lg/ml. Susceptibility tests were carried out
in high resolution medium (14.67 g HR-Medium [Oxoid GmbH], 1 g
NaHCO3, 0.2 M phosphate buffer [pH 7.2]), using a previously
described microdilution method [50]. Readings were done after 48 h.
FACS analysis. Fluorescence-activated cell sorter (FACS) analysis
was performed with a FACSCalibur cytometry system equipped with
an argon laser emitting at 488 nm (Becton Dickinson). Fluorescence
was measured on the FL1 ﬂuorescence channel equipped with a 530-
nm band-pass ﬁlter. Twenty thousand cells were analyzed per sample
and were counted at low ﬂow rate. Fluorescence and forward scatter
data were collected by using logarithmic ampliﬁers. The mean
ﬂuorescence values were determined with CellQuest Pro (Becton
Dickinson) software.
DNA microarray analysis. The nucleotide sequences correspond-
ing to 6,165 ORFs for C. albicans were downloaded from the Galar
Fungail European Consortium (Assembly 6, http://www.pasteur.fr/
Galar_Fungail/CandidaDB). Following the Affymetrix Design Guide,
we designed two separate probe sets for each ORF, each consisting of
13 perfect match and 13 mismatch overlapping 25 bp oligonucleo-
tides, to the 39 600 bp region. For ORFs less than 600 bp in length, the
sequence was divided in two equal segments for subsequent design
procedures. For quality control and normalization purposes, we
made 2–3 additional probe sets spanning the entire sequence of the
C. albicans 18S rRNA (GenBank Accession M60302), genes encoding
GAPDH, actin and Mdr1p (Bmr1p) in addition to the standard
Affymetrix controls (BioB, C, D, cre, DAP, PHE, LYS, THR). The
probe selection was performed by the Chip Design group at
Affymetrix, Inc. using their proprietary algorithm to calculate probe
set scores, which includes a probe quality metric, cross-hybridization
penalty, and gap penalty. The probe sets were then examined for
cross-hybridization against all other sequences in the C. albicans
genome as well as a number of constitutively expressed genes and
rRNA from other common organisms. Consequently, for some target
regions we were not able to design high quality probe sets. In the end,
the GeneChip contained 10,736 probe sets including 9 controls, 6,123
unique ORFs, and duplicate probe sets for 4,604 ORFs. The duplicate
probe sets are made to distinct regions of the ORF, thereby allowing 2
independent measurements of the mRNA level for that particular
gene. The C. albicans custom Affymetrix NimbleExpress Arrays
(CAN04a530004N) were manufactured by NimbleGen Systems [51]
per our speciﬁcation.
RNA preparation for microarrays. Total RNA was isolated using
the hot SDS-phenol method [52]. Frozen cells were suspended in 12
ml of 50 mM sodium acetate (pH 5.2), 10 mM EDTA at room
temperature, after which 1 ml of 20% sodium dodecyl sulphate and
12 ml of acid phenol (Fisher Scientiﬁc) were added. This mixture was
incubated 10 min at 65 8C with mixing each minute, cooled on ice for
5 min, and centrifuged for 15 min at 12,000g. Supernatants were
transferred to new tubes containing 15 ml of chloroform, mixed, and
centrifuged at 200g for 10 min. The aqueous layer was removed to
new tubes, RNA was precipitated with 1 vol isopropanol and 0.1 vol 2
M sodium acetate (pH 5.0), and then collected by centrifugation at
17,000g for 35 min at 4 8C. The RNA pellet was suspended in 10 ml of
70% ethanol, collected again by centrifugation, and suspended in
nuclease-free water.
cRNA synthesis and labeling. Immediately prior to cDNA syn-
thesis, the purity and concentration of RNA samples were deter-
mined from A260/A280 readings, and RNA integrity was determined by
capillary electrophoresis using the RNA 6000 Nano Laboratory-on-a-
Chip kit and Bioanalyzer 2100 (Agilent Technologies) as per the
manufacturer’s instructions. First and second strand cDNA was
synthesized from 15 lg total RNA using the SuperScript Double-
Stranded cDNA Synthesis Kit (Invitrogen) and oligo-dT24-T7 primer
(PrOligo) according to the manufacturer’s instructions. cRNA was
synthesized and labeled with biotinylated UTP and CTP by in vitro
transcription using the T7 promoter-coupled double-stranded cDNA
as template and the Bioarray HighYield RNA Transcript Labeling Kit
(ENZO Diagnostics). Double-stranded cDNA synthesized from the
previous steps was washed twice with 70% ethanol and suspended in
22 ll of RNase-free water. The cDNA was incubated as recommended
with reaction buffer, biotin-labeled ribonucleotides, dithtiothreitol,
RNase inhibitor mix, and T7 RNA polymerase for 5 h at 37 8C. The
labeled cRNA was separated from unincorporated ribonucleotides by
passing through a CHROMA SPIN-100 column (Clontech) and
ethanol precipitated at  20 8C overnight.
Oligonucleotide array hybridization and analysis. The cRNA pellet
was suspended in 10 ll of RNase-free water and 10 lg was fragmented
by ion-mediated hydrolysis at 95 8C for 35 min in 200 mM Tris-
acetate (pH 8.1), 500 mM potassium acetate, 150 mM magnesium
acetate. The fragmented cRNA was hybridized for 16 h at 45 8C to the
C. albicans NimbleExpress GeneChip arrays. Arrays were washed at 25
8C with 63SSPE, 0.01% Tween 20 followed by a stringent wash at 50
8C with 100 mM MES, 0.1 M NaCl, 0.01% Tween 20. Hybridizations
and washes employed the Affymetrix Fluidics Station 450 using their
standard EukGE-WS2v5 protocol. The arrays were then stained with
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ﬂuorescence intensities were determined using the GCS 3000 high-
resolution confocal laser scanner (Affymetrix). The scanned images
were analysed using software resident in GeneChip Operating System
v2.0 (Affymetrix). Sample loading and variations in staining were
standardized by scaling the average of the ﬂuorescent intensities of all
genes on an array to a constant target intensity (250). The signal
intensity for each gene was calculated as the average intensity
difference, represented by [R(PM   MM)/(number of probe pairs)],
where PM and MM denote perfect-match and mismatch probes.
Microarray data analysis. The scaled gene expression values from
GeneChip Operating System v2.0 software were imported into
GeneSpring 7.2 software (Agilent Technologies) for preprocessing
and data analysis. Probe sets were deleted from subsequent analysis if
they were called absent by the Affymetrix criterion and displayed an
absolute value below 20 in all experiments. The expression value of
each gene was normalized to the median expression of all genes in
each chip as well as the median expression for that gene across all
chips in the study. Pairwise comparison of gene expression was
performed for each matched experiment. Among direct comparisons
between matched clinical isolates, genes were considered to be
differentially expressed if their change in expression was   1.5-fold in
three independent experiments.
Quantitative real-time RT-PCR. An aliquot of the RNA prepara-
tions from the samples used in the microarray experiments was saved
for quantitative real-time RT-PCR follow-up studies. First-strand
cDNAs were synthesized from 2 lg of total RNA in a 21-ll reaction
volume using the SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen) in accordance with the manufacturer’s instructions.
Quantitative real-time PCRs were performed in triplicate using the
7000 Sequence Detection System (Applied Biosystems). Independent
PCRs were performed using the same cDNA for both the gene of
interest and the 18S rRNA, using the SYBR Green PCR Master Mix
(Applied Biosystems). Gene-speciﬁc primers were designed for the
gene of interest and the 18S rRNA using Primer Express software
(Applied Biosystems) and the Oligo Analysis & Plotting Tool
(QIAGEN) and are shown in Table S5. The PCR conditions consisted
of AmpliTaq Gold activation at 95 8C for 10 min, followed by 40 cycles
of denaturation at 95 8C for 15 s and annealing/extension at 60 8C for 1
min. A dissociation curve was generated at the end of each PCR cycle
to verify that a single product was ampliﬁed using software provided
with the 7000 Sequence Detection System. The change in ﬂuorescence
of SYBR Green I dye in every cycle was monitored by the system
software, and the threshold cycle (CT) above the background for each
reaction was calculated. The CT value of 18S rRNA was subtracted
from that of the gene of interest to obtain a DCT value. The DCT value
of an arbitrary calibrator (e.g., untreated sample) was subtracted from
the DCT value of each sample to obtain a DDCT value. The gene
expression level relative to the calibrator was expressed as 2 DDCT.
Supporting Information
Figure S1. Analysis of MDR1 Expression in Clinical C. albicans Isolates,
mrr1D Mutants, and Strains Expressing MRR1 Gain-of-Function
Alleles by Quantitative Real-Time RT-PCR
Found at doi:10.1371/journal.ppat.0030164.sg001 (90 KB PDF).
Table S1. Genes that Were Differentially Expressed in the Flucoazole-
Resistant Isolates F5, G5, and 6692 as Compared with the Matched
Fluconazole-Susceptible Isolates F1, G1, and 5833, Respectively
Sheet 1 shows all upregulated genes; genes that were upregulated in
two or all three drug-resistant isolates are highlighted in light orange
and dark orange, respectively. Sheet 2 shows all downregulated genes;
genes that were downregulated in two or all three drug-resistant
isolates are highlighted in light green and dark green, respectively.
Found at doi:10.1371/journal.ppat.0030164.st001 (510 KB XLS).
Table S2. C. albicans Strains Used in This Study
Found at doi:10.1371/journal.ppat.0030164.st002 (137 KB DOC).
Table S3. Allelic Differences in the MRR1 Alleles of Isolates F2, F5,
G2, and G5
Found at doi:10.1371/journal.ppat.0030164.st003 (166 KB DOC).
Table S4. Genes that Were Differentially Expressed in the mrr1D
Mutants of the Drug-Resistant Isolates F5 and G5 as Compared with
Their Parental Strains
Sheet 1 shows all downregulated genes; sheet 2 shows all upregulated
genes. Genes that were downregulated or upregulated in mrr1D
mutants of both F5 and G5 are highlighted in green and orange,
respectively.
Found at doi:10.1371/journal.ppat.0030164.st004 (260 KB XLS).
Table S5. Primers Used in This Study
Found at doi:10.1371/journal.ppat.0030164.st005 (40 KB DOC).
Accession Numbers
The coding sequences of the MRR1 alleles described in this study
have been deposited in GenBank (http://www.ncbi.nlm.nih.
gov/Genbank/index.html) with the following accession numbers:
EU139261 (MRR1
F2–1), EU139262 (MRR1
F2–2), EU139263 (MRR1
F5),
EU139264 (MRR1
G2–1), EU139265 (MRR1
G2–2), EU139266 (MRR1
G5).
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